AbbVie is a publicly-traded biopharmaceutical company that was founded in 2013 as a separate entity from Abbott. Rijken oversees 1,200 people in the Middle East, Africa, and Russia. In October 2022, AbbVie signed a collaboration with the Department of Health in Abu Dhabi for manufacturing and clinical research. Globally, AbbVie recorded over $58 billion in revenues in 2022. Rijken has almost 20 years of experience at both Abbott and AbbVie, in which he has held commercial leadership roles in Chicago, Shanghai, Singapore, Sydney, Paris, Amsterdam, and Dubai.